● Recruiting

A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)

Condition: Multiple Myeloma · Newly Diagnosed Multiple Myeloma · Sponsor: GlaxoSmithKline

PhasePhase 3

Planned participants520

Who can joinAll sexes, 18 Years to no upper limit

Healthy volunteersNo

About this study

The purpose of this Phase 3 study is to evaluate if BRd prolongs progression free survival (PFS) and/or improves minimal residual disease (MRD) negative status compared with DRd in participants with TI-NDMM.

This description comes directly from the study's public registry record.

Talk to the study team

US GSK Clinical Trials Call Center · 877-379-3718 · GSKClinicalSupportHD@gsk.com

EU GSK Clinical Trials Call Center · +44 (0) 20 89904466 · GSKClinicalSupportHD@gsk.com

Always discuss trial participation with your own doctor first.

Locations (181)

GSK Investigational Site	Mobile, Alabama, United States	Recruiting
GSK Investigational Site	Phoenix, Arizona, United States	Recruiting
GSK Investigational Site	Beverly Hills, California, United States	Recruiting
GSK Investigational Site	Pasadena, California, United States	Recruiting
GSK Investigational Site	Aurora, Colorado, United States	Recruiting
GSK Investigational Site	Washington D.C., District of Columbia, United States	Recruiting
GSK Investigational Site	Englewood, Florida, United States	Recruiting
GSK Investigational Site	Lady Lake, Florida, United States	Recruiting
GSK Investigational Site	Pembroke Pines, Florida, United States	Recruiting
GSK Investigational Site	Saint Augustine, Florida, United States	Recruiting
GSK Investigational Site	Atlanta, Georgia, United States	Recruiting
GSK Investigational Site	Portland, Maine, United States	Recruiting

+ 169 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06679101